Skip to main content
SpringerLink
Log in

Thrombozytenaggregationshemmer

Inhibition of platelet aggregation

  • leitlinien für die praxis
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Zusammenfassung

Akute atherothrombotische Komplikationen tragen, im Rahmen der beschleunigten Atherosklerose, zur kardiovaskulären Morbidität und Mortalität diabetischer Patienten bei. Die Hemmung der Thrombozytenaggregation kann das Risiko für das Auftreten akuter atherothrombotischer Komplikationen reduzieren. Der vorliegende Artikel stellt die Behandlungsvorschläge der österreichischen Diabetesgesellschaft zum Einsatz von Hemmern der Thrombozytenaggregation dar.

Summary

Acute thrombotic complications as a key feature of accelerated atherothrombotic disease typically precipitate cardiovascular events and therefore strongly contribute to cardiovascular morbidity and mortality in diabetic patients. Inhibition of platelet aggregation can reduce the risk for acute atherothrombosis. The present article represents the recommendations of the Austrian Diabetes Association for the use of antiplatelet drugs in diabetic patients according to current scientific evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. The antithrombotic trialists collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.

    Article  Google Scholar 

  2. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306–13.

    Article  CAS  PubMed  Google Scholar 

  3. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134–41.

    Article  CAS  PubMed  Google Scholar 

  4. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O’Brien I, Semple C, Petrie J, Gordon D, Pringle S. MacWalter R, Prevention of Progression of Arterial Disease and Diabetes Study Group, Diabetes Registry Group, Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.

    Article  PubMed  PubMed Central  Google Scholar 

  5. The antithrombotic trialists collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1. Medizinische Abteilung, Hanuschkrankenhaus, Wien, Österreich

    Thomas C. Wascher

  2. Abteilung für Innere Medizin und Kardiologie/VIVIT-Institut, Landeskrankenhaus Feldkirch, Feldkirch, Österreich

    Christoph H. Säly

Authors
  1. Thomas C. Wascher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph H. Säly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas C. Wascher.

Ethics declarations

Interessenkonflikt

T. C. Wascher und C.H. Säly haben keinen Interessenkonflikt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wascher, T.C., Säly, C.H. Thrombozytenaggregationshemmer. Wien Klin Wochenschr 128 (Suppl 2), 71–72 (2016). https://doi.org/10.1007/s00508-015-0932-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-015-0932-2

Schlüsselwörter

Keywords

Search

Navigation